Company intelligence / Profile preview

CamAPS FX

Cambridge, England, United Kingdomcamdiab.com ↗

Ownership: Private
Development stage: Commercial

Overview

Randomized clinical trials have shown that the use of the CamAPS FX system significantly increases time-in-range and reduces HbA1c without increasing hypoglycemia risk. The system has been extensively tested and is considered one of the leading algorithms for automated glycemic control in type 1 diabetes.

Therapeutic areas: EndocrinologyWomen's Health
Modalities: DeviceNon-pharmacological therapy
Industry: Digital Health Medical Devices

Drug pipeline

1 asset

CamAPS FX

Commercial

Indications: Type 1 diabetes

Partnerships

Abbott (for integration with FreeStyle Libre CGM)Ypsomed (for mylife YpsoPump integration)

Beyond the preview

Go deeper on CamAPS FX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CamAPS FX.

Explore the full profile